Radiopharm Theranostics Ltd (RAD) - Total Assets
Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) holds total assets worth AU$86.48 Million AUD (≈ $61.19 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RAD net asset value for net asset value and shareholders' equity analysis.
Radiopharm Theranostics Ltd - Total Assets Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's total assets have evolved over time, based on quarterly financial data.
Radiopharm Theranostics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Radiopharm Theranostics Ltd's total assets of AU$86.48 Million consist of 46.1% current assets and 53.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 33.7% |
| Accounts Receivable | AU$10.40 Million | 12.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$53.47K | 0.1% |
| Intangible Assets | AU$46.57 Million | 53.9% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RAD market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Radiopharm Theranostics Ltd's current assets represent 46.1% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 33.7% of total assets in 2025, down from 81.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 167699.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 53.9% of total assets.
Radiopharm Theranostics Ltd Competitors by Total Assets
Key competitors of Radiopharm Theranostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Radiopharm Theranostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.67 | 1.30 | 0.21 |
| Quick Ratio | 2.67 | 1.36 | 0.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$24.92 Million | AU$5.27 Million | AU$-124.70K |
Radiopharm Theranostics Ltd - Advanced Valuation Insights
This section examines the relationship between Radiopharm Theranostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 20.1% |
| Total Assets | AU$86.48 Million |
| Market Capitalization | $31.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Radiopharm Theranostics Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Radiopharm Theranostics Ltd's assets grew by 20.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Radiopharm Theranostics Ltd (2021–2025)
The table below shows the annual total assets of Radiopharm Theranostics Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$86.48 Million ≈ $61.19 Million |
+20.05% |
| 2024-06-30 | AU$72.04 Million ≈ $50.97 Million |
-3.89% |
| 2023-06-30 | AU$74.95 Million ≈ $53.03 Million |
-10.11% |
| 2022-06-30 | AU$83.38 Million ≈ $59.00 Million |
+249260.88% |
| 2021-06-30 | AU$33.44K ≈ $23.66K |
-- |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more